ETANA OFFICIALLY APOINTED BY THE MINISTRY OF HEALTH AS A CENTER OF EXCELLNCE FOR VACCINE AND BIOTECHNOLOGY

Jakarta, August 28, 2025 – PT Etana Biotechnologies Indonesia (Etana) has officially been designated as one of the Centers of Excellence for Vaccine and Biotechnology Development by the Ministry of Health of the Republic of Indonesia. The designation is stated in the Decree of the Director General of Pharmaceuticals and Medical Devices No. HK.02.02/E/1504/2025.

As a Center of Excellence, Etana has been mandated to conduct vaccine and biotechnology product research and development, enhance human resource capacity, and facilitate collaborative research among member countries of the Organization of Islamic Cooperation (OIC).

“This designation is a significant boost for Etana to strengthen its commitment to research development, expand collaborations, and accelerate innovation both in Indonesia and across OIC member countries. We are ready to enhance research capacity, technology, and human resources so that Indonesia can play a more strategic role in the global healthcare ecosystem,” said Andreas Donny Prakasa, Head of Corporate Relations at Etana.

Etana will also continue to accelerate the development of its vaccine and biotechnology product pipeline, improve the capacity of researchers and healthcare professionals through various training programs, and broaden research collaborations with international partners.

“As a Center of Excellence, Etana plays a strategic role not only in strengthening internal research but also as a collaborative platform with universities, research institutions, and the pharmaceutical industry at both national and global levels. With this step, Indonesia will be better prepared to face future health challenges,” Donny added.

This designation will remain valid for three years, during which Etana is required to regularly report its research and development progress on vaccines and biotechnology products to the Directorate General of Pharmaceuticals and Medical Devices.

About Etana

Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.

Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com.